BEMÆRK: Ansøgningsfristen er overskredet
We are offering an exciting opportunity to join a pioneering biomedical research institute dedicated to innovation and science. This postdoctoral position provides ample opportunities for independent works, supervision of younger researchers, and professional growth.
The tumor-infiltrating lymphocyte (TIL) group at the National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark (Group Leader: Associate Prof. Marco Donia), is seeking a highly motivated postdoctoral researcher with advanced skills in cell biology, immunology, or genomic analysis of cancer for a research project on acquired resistance to cancer immunotherapy. The position has an expected duration of 2 years, with the possibility of extension for an additional 2 years. It is available immediately.
The research project will focus on characterizing acquired resistance to cancer immunotherapy, particularly to TIL therapy, using advanced genomic, spatial, cellular, and in vivo assays. For more information, please refer to our recent manuscript in the New England Journal of Medicine [1], as well as a previous pilot study where we characterized acquired resistance to anti-LAG-3 plus anti-PD-1 [2]. The project is fully funded. More information is available at
https://researchleaderprogramme.com/recipients/marco-donia/.
The TIL group's primary objective is to leverage innovative knowledge on the interaction of TILs with tumors to develop novel therapies for cancer treatment. Our research is focused on three lines of investigation: 1) Acquired Resistance to Immunotherapy (Translational), 2) Functional Characterization of tumor-reacting TILs (Translational), and 3) Real-world Evidence in Cancer Immunotherapy (Clinical-Epidemiological). The research group is young and currently consists of six additional full-time researchers with diverse backgrounds in medicine, biology, and bioinformatics. The Principal Investigator (PI) is employed 50% in research and 50% in the clinic. As such, the postdoctoral researcher will have ample opportunities for leadership within the group, as well as enjoy a high level of independence and professional growth.
CCIT-DK specializes in dissecting the cellular and molecular mechanisms that regulate anti-tumor immunity and utilizes this knowledge to develop next-generation cancer immunotherapies. As part of the Capital Region of Denmark Health Organization, CCIT-DK offers broad training possibilities and a highly collaborative environment for basic and translational cancer immunology research. Currently, approximately 60 highly qualified scientists and clinicians work at CCIT-DK.
Qualifications
- Ph.D. in Immunology, Biology, Medicine, or related fields
- Strong skills in immunology and molecular biology, with a specific focus on human diseases and/or cancer
- Bioinformatics skills (preferred)
- Experience with in vivo studies (preferred)
- Ability to work independently
- Effective communication and presentation skills
- Mentoring mindset towards younger scientists
- A highly innovative research project (please inquire for more information)
- Broad professional growth opportunities
- Access to state-of-the-art technologies
- Access to a world-unique biobank for studying the interaction of T cells and autologous tumors
- Highly competitive salary, based on qualifications, including holiday and pension allowance. Reduced tax-rate for PhDs from abroad may apply
(https://www.bdo.dk/en-gb/taxwatch-articles-2021/tax-scheme-for-foreign-researchers-and-highly-paid-employees )
Interested applicants should send a CV, cover letter with a statement of research interests and any other supporting document.
Deadline: Please send your application as soon as possible (position already available), but not later than January 7th 2024”
Additional info and contacts
For more information, please contact Associate Professor Marco Donia.
E-mail: marco.donia@regionh.dk
Phone: +45 38689339
CCIT Website:
https://www.herlevhospital.dk/ccit-denmark/Sider/default.aspx
TIL group page:
https://www.herlevhospital.dk/ccit-denmark/organisation/Sider/TIL-group-2.aspx
LinkedIn page of group leader, Marco Donia:
https://www.linkedin.com/in/marcodonia/
References
[1] https://www.nejm.org/doi/10.1056/NEJMoa2210233
[2] https://aacrjournals.org/cancerimmunolres/article-abstract/10/10/1254/709279/Coexisting-Alterations-of-MHC-Class-I-Antigen?redirectedFrom=fulltext
INFORMATIONER OM STILLINGEN:
- Arbejdspladsen ligger i:
Herlev Kommune
-Virksomheden tilbyder:
Tidsbegrænset ansættelse: fuldtid
-Arbejdsgiver:
Herlev Hospital, Borgmester Ib Juuls Vej , 2730 Herlev
-Ansøgning:
Ansøgningsfrist: 07-01-2024; - ansøgningsfristen er overskredet
Se mere her: https://job.jobnet.dk/CV/FindWork/Details/5949475
